CD27 and B-cell non-Hodgkin lymphoma: These investigations demonstrate that agonistic anti-CD27 can improve the anti-tumor efficacy of a tumor-targeting mAb to B cell lymphoma in a way not seen with other immunomodulatory mAbs.